Quantitative analysis of amyloid deposition in Alzheimer disease using PET and the radiotracer11C-AZD2184

Journal of Nuclear Medicine

Volumn 55, Issue 6, 2014, Pages 932-938

  Ito, Hiroshi ^a   Shimada, Hitoshi ^a   Shinotoh, Hitoshi ^a   Takano, Harumasa ^a   Sasaki, Takeshi ^a   Nogami, Tsuyoshi ^a   Suzuki, Masayuki ^a   Nagashima, Tomohisa ^a   Takahata, Keisuke ^a   Seki, Chie ^a   Kodaka, Fumitoshi ^a   Eguchi, Yoko ^a   Fujiwara, Hironobu ^a   Kimura, Yasuyuki ^a   Hirano, Shigeki ^a   Ikoma, Yoko ^a   Higuchi, Makoto ^a   Kawamura, Kazunori ^a   Fukumura, Toshimitsu ^a   Lindström B̈̈oo, Éva ^b   Farde, Lars ^b   Suhara, Tetsuya ^a   more..

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer; Amyloid; AZD2184; PET

Indexed keywords

AMYLOID; CARBON 5 (6 [[TERTBUTYL(DIMETHYL)SILYL]OXY] 1,3 BENZOTHIAZOL 2 YL)PYRIDIN 2 AMINE C 11; MYELIN; TRACER; UNCLASSIFIED DRUG; 2-(6-(METHYLAMINO)PYRIDIN-3-YL)-1,3-BENZOTHIAZOL-6-OL; AMINOPYRIDINE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE;

ACCURACY; ADULT; AGED; ALZHEIMER DISEASE; ANATOMICAL VARIATION; ARTICLE; BIOACCUMULATION; BLOOD SAMPLING; BRAIN REGION; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL EXAMINATION; CONTROLLED STUDY; DISTRIBUTION VOLUME; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; WHITE MATTER; ARTERY; BIOLOGICAL MODEL; DIAGNOSTIC USE; KINETICS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMINOPYRIDINES; AMYLOID; ARTERIES; BENZOTHIAZOLES; FEMALE; HUMANS; KINETICS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POSITRON-EMISSION TOMOGRAPHY;

EID: 84903147555     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.133793     Document Type: Article

References (29)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-259.
2. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256:184-185.
3. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740-2754.
4. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306-319. (Pubitemid 38269583)
5. 18F-AV-45: a PET agent for Aβ plaques in the brain. J Nucl Med. 2009;50:1887-1894.
6. Johnson AE, Jeppsson F, Sandell J, et al. AZD2184: a radioligand for sensitive detection of beta-amyloid deposits. J Neurochem. 2009;108:1177-1186.
7. 11C]AZD2184. Eur J Nucl Med Mol Imaging. 2009;36:1859-1863.
8. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944. (Pubitemid 14076461)
9. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414. (Pubitemid 23346995)
10. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
11. 11C]AZD2184: positron emission tomography examination and metabolite analysis in cynomolgus monkeys. Synapse. 2010;64:733-741.
12. Matsumoto K, Kitamura K, Mizuta T, et al. Performance characteristics of a new 3-dimensional continuous-emission and spiral-transmission high-sensitivity and high-resolution PET camera evaluated with the NEMA NU 2-2001 standard. J Nucl Med. 2006;47:83-90. (Pubitemid 46768516)
13. Ishikawa A, Kitamura K, Mizuta T, et al. Implementation of on-the-fly scatter correction using dual-energy window method in continuous 3D whole body PET scanning. IEEE Nucl Sci Symp Conf Rec. 2005;5:2497-2500.
14. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol. 1984;15:217-227. (Pubitemid 14164735)
15. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539. (Pubitemid 47301451)
16. Marquardt D. An algorithm for least-squares estimation of nonlinear parameters. J Soc Ind Appl Math. 1963;11:431-441.
17. Ito H, Ota M, Ikoma Y, et al. Quantitative analysis of dopamine synthesis in human brain using positron emission tomography with L-[β-11C]DOPA. Nucl Med Commun. 2006;27:723-731. (Pubitemid 44213030)
18. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab. 2005;25:1528-1547. (Pubitemid 41541962)
19. Kudo Y, Okamura N, Furumoto S, et al. 2-(2-[2-dimethylaminothiazol-5-yl] ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med. 2007;48:553-561. (Pubitemid 47571409)
20. 11C]raclopride binding. J Cereb Blood Flow Metab. 1998;18:941-950.
21. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4′- methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 2003;23:2086-2092. (Pubitemid 36368896)
22. Klunk WE, Lopresti BJ, Ikonomovic MD, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci. 2005;25:10598-10606. (Pubitemid 41681907)
23. Fodero-Tavoletti MT, Rowe CC, McLean CA, et al. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med. 2009;50:198-204.
24. 11C]-2-(4′-methylaminophenyl)- 6-hydroxybenzothiazole. Ann Neurol. 2011;69:673-680.
25. Ito H, Takahashi H, Arakawa R, Takano H, Suhara T. Normal database of dopaminergic neurotransmission system in human brain measured by positron emission tomography. Neuroimage. 2008;39:555-565. (Pubitemid 350117640)
26. 11C]WAY-100635: PET with anatomic standardization technique. J Nucl Med. 1999;40:102-109.
27. 11C-PiB PET studies. J Nucl Med. 2012;53:622-628.
28. Masliah E, Terry RD, Mallory M, Alford M, Hansen LA. Diffuse plaques do not accentuate synapse loss in Alzheimer's disease. Am J Pathol. 1990;137:1293-1297.
29. Price JL. Diagnostic criteria for Alzheimer's disease. Neurobiol Aging. 1997;18:S67-S70. (Pubitemid 27454699)